Skip to content
An Initiative of AVAC
Search
Back to Events Archive

The Future of PrEP: Implementation studies to guide the rollout of new PrEP products

Tuesday13June
Virtual

Recording / Slides

As new PrEP products move out of clinical trials and toward market entry, implementation research has a pivotal role to play in guiding the introduction and scale-up of these new products in real-world service delivery settings. In this webinar, we will hear from the investigators of new implementation studies offering choice of PrEP products, including oral PrEP, injectable cabotegravir, and the dapivirine vaginal ring. Presenters will discuss their study designs and PrEP choice interventions, and webinar attendees will learn how these groundbreaking studies spanning diverse geographies and priority populations will generate critical evidence and lessons for HIV prevention efforts across the globe.

Speakers and Panelists
Kristine Torjesen, FHI 360
Sanele Ngulube, Pangaea Zimbabwe AIDS Trust, MOSAIC NextGen Squad
Elizabeth Irungu, Jhpiego
James Ayieko, Kenya Medical Research Institute
Catherine Koss, University of California, San Francisco
Sara Allinder, Georgetown University
Inês Dourado, Collective Health Institute / Federal University of Bahia, Brazil

This webinar is part of the Global PrEP Learning Network webinar series hosted by the PEPFAR– and USAID– supported MOSAIC project. Learn more about MOSAIC and the PrEP Learning Network by visiting PrEPWatch.

Topic(s): Research

Product(s): Cabotegravir, Dapivirine Vaginal Ring, Oral PrEP

Featured Resources

External Link

Pre-Exposure Prophylaxis Implementation Gaps among People Vulnerable to HIV Acquisition: A cross-sectional analysis in two communities in western Kenya, 2021–2023

This article, from Journal of the International AIDS Society, examines PrEP awareness, uptake, and persistence among participants enrolling into an HIV incidence cohort in Kenya.
Document

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

External Link

Initiation and Continued Use of Oral Pre-Exposure Prophylaxis among Pregnant and Postpartum Women in South Africa (PrEP-PP): A demonstration cohort study

This article from The Lancet HIV describes the results of a demonstration study in South Africa, PrEP-PP, to integrate oral PrEP provision into public clinics offering antenatal and postnatal care to pregnant and lactating people.
External Link

Acceptability of Six-Monthly PrEP Dispensing Supported with Interim HIV Self-Testing to Simplify PrEP Delivery in Kenya: Findings from qualitative research

This article from BMC Health Services Research discusses the results of a pilot in Kenya to explore the acceptability of dispensing PrEP twice a year, with interim HIV self-testing, versus quarterly, with clinic-based HIV testing.
Document

CAB PrEP Introduction Situation Analysis – South Africa – 2024

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.
External Link

Dynamic Choice HIV Prevention with Cabotegravir Long-acting Injectable in Rural Uganda and Kenya: A randomised trial extension

This article from The Lancet HIV discusses the results of the SEARCH dynamic choice study conducted in Kenya and Uganda, comparing outcomes between one group offered a choice between oral PrEP, post-exposure prophylaxis, and cabotegravir for PrEP, and a second group receiving the standard of care.
External Link

Adolescent Girls and Young Women Overcoming Adherence Challenges with Vaginal and Oral PrEP Use: A longitudinal qualitative study from a crossover trial in South Africa, Uganda, and Zimbabwe

This article from AIDS and Behavior explores South African, Ugandan, and Zimbabwean adolescent girls and young women’s experiences in a crossover trial of two HIV prevention products: daily oral PrEP and a monthly dapivirine vaginal ring.
Presentation

Dapivirine Vaginal Ring Early Market Access Vehicle (EMAV)

In response to the voices of adolescent girls and women who need more HIV prevention choices, The Global Fund (GF) and the Children Investment Fund Foundation (CIFF) have partnered to make dapivirine vaginal rings available in GF-supported countries through an early market access vehicle. See below for EMAV request forms. For guidance on how to…
Spreadsheet

Access Workbook for Cabotegravir for PrEP, Dapivirine Vaginal Ring, and Lenacapavir for PrEP

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP, the dapivirine vaginal ring (DVR), and lenacapavir (LEN) for PrEP for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit…

PrEP Ring Instructional Video

The PrEP Ring is a long-acting vaginal ring that a woman can use to reduce the risk of HIV transmission during vaginal sex. Women urgently need options for HIV prevention, so that they can choose that best meets their needs and circumstances. Please click on the video link(s) below to see How to Use the…